Drug intelligence / Profile preview

veliflapon

Development stage: Phase 3
Lead developer: deCODE genetics
Modality: Small Molecules

Overview

Veliflapon is an investigational small molecule drug that acts as a selective inhibitor of the enzyme 5-lipoxygenase activating protein (FLAP). By inhibiting FLAP, veliflapon blocks the biosynthesis of leukotrienes, which are inflammatory mediators implicated in cardiovascular disease. Veliflapon has been primarily developed for the prevention of acute cardiovascular events such as heart attack and stroke in patients with coronary artery disease. The drug has reached Phase 3 clinical trials, notably being studied for its efficacy in reducing risk among African American patients with a history of unstable angina or myocardial infarction. It was originally developed by deCODE genetics[8][10].

Brand names: veliflapon
Other names: veliflapon128253-31-6

Targets

FLAP (Arachidonate 5-lipoxygenase-activating protein)

Beyond the preview

Go deeper on veliflapon.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on veliflapon.

Explore the full profile